Alkermes (ALKS) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Alkermes (ALKS) over the past year, gaining 404.7% versus a gain of 33.9%. Over five years, ALKS leads with a +30.9% price change compared with -60.5% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.46 billion vs $6.95 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | SYRE |
|---|---|---|
| Share price | $41.45 | $80.85 |
| Market cap | $6.95B | $7.46B |
| 1-day change | -0.49% | +0.92% |
| YTD return | +48.12% | +146.79% |
| 1-year return | +33.91% | +404.68% |
| 5-year return | +30.87% | -60.46% |
| P/E ratio (TTM) | 109.07 | — |
| Forward P/E | 22.92 | — |
| EPS (TTM) | $0.38 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $0 |
| Revenue growth (YoY) | -5.25% | — |
| Net income (latest FY) | $241.66M | $-155.20M |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | — |
| Net margin | 16.37% | — |
| 52-week high | $55.67 | $110.18 |
| 52-week low | $27.00 | $17.65 |
| Distance from 52-week high | -25.55% | -26.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.47% | +48.68% |
| Average volume | 1.83M | 1.20M |
| Shares outstanding | 167.76M | 92.29M |
| Employees | 2,050 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed ALKS by 370.8 percentage points over the past year.
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
ALKS vs SYRE FAQ
Which is bigger, Alkermes or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.46B compared with $6.95B for Alkermes (ALKS).
Which stock has performed better over the past year, ALKS or SYRE?
SYRE returned +404.68% over the past 12 months, compared with +33.91% for ALKS (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.